The Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Should risk-adapted MM treatment be informed by age or frailty status?

In this podcast, Hira Mian discusses the relationship between age and frailty status, sharing her perspective on how they may inform treatment strategies for patients with multiple myeloma. Mian examines the influence of age on frailty status, but notes other influential factors featured in the International Myeloma Working Group (IMWG) frailty score. Mian concludes with the importance of a comprehensive frailty assessment to inform a risk-adapted treatment plan.

Hosted on Acast. See acast.com/privacy for more information.